Safety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia—An Inpatient Welfare Institution-Based Cross-Sectional Study
Authors:
- Aleksandra D. PetrovicAPAleksandra D. Petrovic
- Ana M. BarjaktarevicABAna M. Barjaktarevic
- Olivera Z. KosticOKOlivera Z. Kostic
- Sara S. MijailovicSMSara S. Mijailovic
- Slobodan M. JankovicSJSlobodan M. Jankovic
- Marija V. AndjelkovicMAMarija V. Andjelkovic
- Marijana S. Stanojevic PirkovicMPMarijana S. Stanojevic Pirkovic
- Katarina D. Parezanovic IlicKIKatarina D. Parezanovic Ilic
- Vladimir S. JanjicVJVladimir S. Janjic
- Jana MojsilovicJMJana Mojsilovic
- Jana ArsenijevicJAJana Arsenijevic
- Danijela B. JovanovicDJDanijela B. Jovanovic
Open Access
- 23 May 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 777
Abstract
Background/Objectives: Adverse effects of antipsychotics represent a significant limiting factor in achieving favorable therapeutic outcomes in the treatment of schizophrenia, and may contribute to a diminished quality of life among affected individuals. The primary objective of this study was to identify and evaluate the adverse effects of antipsychotics in patients diagnosed with schizophrenia who were treated at the social welfare institution, as well as to analyze the impact of these adverse effects on patients’ overall quality of life. Methods: A clinical, observational cross-sectional study was conducted, involving a sample of 278 patients diagnosed with schizophrenia. The patients were assessed in terms of their sociodemographic and clinical characteristics. Adverse effects of antipsychotics were evaluated using The Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale, while quality of life was assessed in the previous study. Results: The average number of adverse effects per patient with schizophrenia was 3.56 for psychiatric, 1.18 for neurological, 2.62 for autonomic, and 7.12 for other side effects. The average UKU score was 17.22 ± 11.04, with significant differences based on accommodation, antipsychotic type, and dosing regimen. UKU scores were negatively correlated with the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) index, Visual Analog Scale (VAS) score, the Quality-of-Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q-SF) score, and the scores of physical and psychological domains of the World Health Organization Quality-of-Life Scale (WHOQOL-BREF). Conclusions: The findings of this study suggest that the presence of antipsychotic-related adverse effects is a significant determinant that can negatively influence the quality of life in patients with schizophrenia. These results underscore the importance of an individualized approach when determining pharmacological treatment strategies in the management of schizophrenia.Keywords
This publication has 25 references indexed in Scilit:
- Health-related quality of life and associated factors among patients with schizophrenia at comprehensive specialised hospitals in the Northwest Ethiopia: a multicentre cross-sectional studyBMJ Open, 2023
- Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophreniaBehavioural Brain Research, 2021
- Quantifying and Categorizing ADRs in Psychiatric Residential Long-Stay Patients Utilizing UKU-SERS ScaleIndian Journal of Psychological Medicine, 2020
- Management of common adverse effects of antipsychotic medicationsWorld Psychiatry, 2018
- Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacyProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2018
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Patient Characteristics, Length of Stay, and Functional Improvement for Schizophrenia Spectrum Disorders: A Population Study of Inpatient Care in Ontario 2005 to 2015The Canadian Journal of Psychiatry, 2016
- Detecting and Managing Adverse Effects of Antipsychotic MedicationsPsychiatric Clinics of North America, 2016
- SchizophreniaNature Reviews Disease Primers, 2015
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987